The present invention provides a compound represented by general formula (I) (in the formula: A is a benzene ring, pyridine ring, or the like； Y1 is an alkylene group having 1-6 carbon atoms, or the like； Y2 is a single bond or the like； Z is -C(=O)-NHSO2R6, an acidic 5-membered heterocycle group, or the like； R1 is a hydrogen atom or the like； R2 is a phenyl group, a 5-membered aromatic heterocycle group, or the like； R3 is a halogen atom, an alkoxy group having 1-6 carbon atoms, or the like； R4 is a hydrogen atom, a halogen atom, or the like； R5 is a hydrogen atom or the like； and R6 represents an alkyl group having 1-6 carbon atoms, or the like) having EP1 receptor antagonism, and a pharmacologically acceptable salt of same. Furthermore, the compound (I) can be used as a therapeutic drug or a preventative drug for various symptoms of LUTS, particularly OABs.
